Your browser doesn't support javascript.
loading
LOXL2 promotes oncogenic progression in alveolar rhabdomyosarcoma independently of its catalytic activity.
Almacellas-Rabaiget, Olga; Monaco, Paola; Huertas-Martinez, Juan; García-Monclús, Silvia; Chicón-Bosch, Mariona; Maqueda-Marcos, Susana; Fabra-Heredia, Isabel; Herrero-Martín, David; Rello-Varona, Santiago; de Alava, Enrique; López-Alemany, Roser; Giangrande, Paloma H; Tirado, Oscar M.
Afiliação
  • Almacellas-Rabaiget O; Sarcoma Research Group, Oncobell Program, Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet de Llobregat, Barcelona, Spain.
  • Monaco P; Sarcoma Research Group, Oncobell Program, Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet de Llobregat, Barcelona, Spain.
  • Huertas-Martinez J; Sarcoma Research Group, Oncobell Program, Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet de Llobregat, Barcelona, Spain.
  • García-Monclús S; Sarcoma Research Group, Oncobell Program, Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet de Llobregat, Barcelona, Spain.
  • Chicón-Bosch M; Sarcoma Research Group, Oncobell Program, Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet de Llobregat, Barcelona, Spain.
  • Maqueda-Marcos S; Sarcoma Research Group, Oncobell Program, Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet de Llobregat, Barcelona, Spain.
  • Fabra-Heredia I; Sarcoma Research Group, Oncobell Program, Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet de Llobregat, Barcelona, Spain.
  • Herrero-Martín D; Sarcoma Research Group, Oncobell Program, Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet de Llobregat, Barcelona, Spain; CIBERONC, Carlos III Institute of Health (ISCIII), Madrid, Spain.
  • Rello-Varona S; Sarcoma Research Group, Oncobell Program, Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet de Llobregat, Barcelona, Spain.
  • de Alava E; CIBERONC, Carlos III Institute of Health (ISCIII), Madrid, Spain; Laboratory of Molecular Pathology, Instituto de Biomedicina de Sevilla (IBiS), Hospital Universitario Virgen Del Rocío/CSIC/Universidad de Sevilla, Sevilla, Spain.
  • López-Alemany R; Sarcoma Research Group, Oncobell Program, Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet de Llobregat, Barcelona, Spain.
  • Giangrande PH; Department of Internal Medicine, Molecular and Cellular Biology Program, Abboud Cardiovascular Research Center, Holden Comprehensive Cancer Center, University of Iowa, Iowa City, IA, USA.
  • Tirado OM; Sarcoma Research Group, Oncobell Program, Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet de Llobregat, Barcelona, Spain; CIBERONC, Carlos III Institute of Health (ISCIII), Madrid, Spain; Institut Català D'Oncologia (ICO), L'Hospitalet de Llobregat, Barcelona, Spain. Electronic addre
Cancer Lett ; 474: 1-14, 2020 04 01.
Article em En | MEDLINE | ID: mdl-31911079
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Biomarcadores Tumorais / Rabdomiossarcoma Alveolar / Carcinogênese / Aminoácido Oxirredutases / Neoplasias Pulmonares Limite: Animals / Female / Humans Idioma: En Revista: Cancer Lett Ano de publicação: 2020 Tipo de documento: Article País de afiliação: Espanha
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Biomarcadores Tumorais / Rabdomiossarcoma Alveolar / Carcinogênese / Aminoácido Oxirredutases / Neoplasias Pulmonares Limite: Animals / Female / Humans Idioma: En Revista: Cancer Lett Ano de publicação: 2020 Tipo de documento: Article País de afiliação: Espanha